Khaldoun Almhanna

Summary

Affiliation: H. Lee Moffitt Cancer Center and Research Institute
Country: USA

Publications

  1. doi Antibody-drug conjugate directed against the guanylyl cyclase antigen for the treatment of gastrointestinal malignancies
    Khaldoun Almhanna
    Department of Gastrointestinal Oncology, H Lee Moffitt Cancer Center and Research Institute, FOB 2, Tampa, FL 334612, USA Electronic address
    Pharmacol Ther 170:8-13. 2017
  2. ncbi Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody-Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies
    Khaldoun Almhanna
    Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, Florida
    Clin Cancer Res 22:5049-5057. 2016
  3. pmc Association between COX-2 expression and effectiveness of COX-2 inhibitors in a phase II trial in patients with metastatic colorectal adenocarcinoma
    Khaldoun Almhanna
    Department of Gastrointestinal Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Anticancer Res 32:3559-63. 2012
  4. ncbi Neoadjuvant or adjuvant therapy for resectable esophageal cancer: is there a standard of care?
    Khaldoun Almhanna
    Gastrointestinal Tumor Program, H Lee Moffitt Cancer Center, Tampa, FL 33612, USA
    Cancer Control 20:89-96. 2013
  5. ncbi Targeting the human epidermal growth factor receptor 2 in esophageal cancer
    Khaldoun Almhanna
    Gastrointestinal Tumor Program, H Lee Moffitt Cancer Center, Tampa, FL 33612, USA
    Cancer Control 20:111-6. 2013
  6. doi Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy
    Ravi Shridhar
    Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL, USA
    Ann Surg Oncol 20:3038-43. 2013
  7. doi Outcomes associated with surgery for T4 esophageal cancer
    Jose M Pimiento
    Program of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA
    Ann Surg Oncol 20:2706-12. 2013
  8. doi Extent of lymphadenectomy does not predict survival in patients treated with primary esophagectomy
    Joyce Wong
    Department of Gastrointestinal Surgery, H Lee Moffitt Cancer Center, Tampa, FL, USA
    J Gastrointest Surg 17:1562-8; discussion 1569. 2013
  9. doi Adjuvant radiation therapy and lymphadenectomy in esophageal cancer: a SEER database analysis
    Ravi Shridhar
    Department of Radiation Oncology, H Lee Moffitt Cancer Center, Tampa, FL 33612, USA
    J Gastrointest Surg 17:1339-45. 2013
  10. doi Body mass index and survival in esophageal adenocarcinoma treated with chemoradiotherapy followed by esophagectomy
    Ravi Shridhar
    Department of Radiation Oncology, H Lee Moffitt Cancer Center, 12902 Magnolia Dr, Tampa, FL 33612, USA
    J Gastrointest Surg 16:1296-302. 2012

Collaborators

Detail Information

Publications38

  1. doi Antibody-drug conjugate directed against the guanylyl cyclase antigen for the treatment of gastrointestinal malignancies
    Khaldoun Almhanna
    Department of Gastrointestinal Oncology, H Lee Moffitt Cancer Center and Research Institute, FOB 2, Tampa, FL 334612, USA Electronic address
    Pharmacol Ther 170:8-13. 2017
    ..Herein we discuss the GCC target and gastrointestinal malignancies where GCC based targeted therapies could further evolve and offer a significant clinical benefit...
  2. ncbi Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody-Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies
    Khaldoun Almhanna
    Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, Florida
    Clin Cancer Res 22:5049-5057. 2016
    ..To assess the safety, tolerability, and preliminary antitumor activity of the investigational anti-guanylyl cyclase C (GCC) antibody-drug conjugate TAK-264 (formerly MLN0264) in adult patients with advanced gastrointestinal malignancies...
  3. pmc Association between COX-2 expression and effectiveness of COX-2 inhibitors in a phase II trial in patients with metastatic colorectal adenocarcinoma
    Khaldoun Almhanna
    Department of Gastrointestinal Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Anticancer Res 32:3559-63. 2012
    ..We evaluated the COX-2 expression in the available tumors from enrolled patients by immunohistochemistry, as well as its correlation with clinical outcome...
  4. ncbi Neoadjuvant or adjuvant therapy for resectable esophageal cancer: is there a standard of care?
    Khaldoun Almhanna
    Gastrointestinal Tumor Program, H Lee Moffitt Cancer Center, Tampa, FL 33612, USA
    Cancer Control 20:89-96. 2013
    ....
  5. ncbi Targeting the human epidermal growth factor receptor 2 in esophageal cancer
    Khaldoun Almhanna
    Gastrointestinal Tumor Program, H Lee Moffitt Cancer Center, Tampa, FL 33612, USA
    Cancer Control 20:111-6. 2013
    ..In addition to presenting data on the HER2 cascade, the authors review clinical trials performed to date and also present the validated standard scoring system for HER2 overexpression in esophageal cancer...
  6. doi Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy
    Ravi Shridhar
    Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL, USA
    Ann Surg Oncol 20:3038-43. 2013
    ..This study was designed to determine the effects of lymph node (LN) harvest on survival in esophageal cancer after neoadjuvant chemoradiation (nCRT)...
  7. doi Outcomes associated with surgery for T4 esophageal cancer
    Jose M Pimiento
    Program of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA
    Ann Surg Oncol 20:2706-12. 2013
    ..T4 esophageal cancer often portends a dismal prognosis even after surgical resection. Historical incomplete resections and poor survival rates often make surgery palliative rather than curative...
  8. doi Extent of lymphadenectomy does not predict survival in patients treated with primary esophagectomy
    Joyce Wong
    Department of Gastrointestinal Surgery, H Lee Moffitt Cancer Center, Tampa, FL, USA
    J Gastrointest Surg 17:1562-8; discussion 1569. 2013
    ..Current guidelines recommend extended lymphadenectomy in patients not receiving neoadjuvant therapy. We reviewed our single institutional experience with nodal harvest for esophageal cancer in a non-neoadjuvant therapy setting...
  9. doi Adjuvant radiation therapy and lymphadenectomy in esophageal cancer: a SEER database analysis
    Ravi Shridhar
    Department of Radiation Oncology, H Lee Moffitt Cancer Center, Tampa, FL 33612, USA
    J Gastrointest Surg 17:1339-45. 2013
    ..This study seeks to determine the effects of postoperative radiation therapy and lymphadenectomy on survival in esophageal cancer...
  10. doi Body mass index and survival in esophageal adenocarcinoma treated with chemoradiotherapy followed by esophagectomy
    Ravi Shridhar
    Department of Radiation Oncology, H Lee Moffitt Cancer Center, 12902 Magnolia Dr, Tampa, FL 33612, USA
    J Gastrointest Surg 16:1296-302. 2012
    ..Body mass index (BMI) has been linked with inferior outcomes in gastrointestinal malignancies. The purpose of this study is to evaluate the effect of BMI on survival in patients with esophageal adenocarcinoma...
  11. doi Phase I study of pre-operative continuous 5-FU and sorafenib with external radiation therapy in locally advanced rectal adenocarcinoma
    Richard Kim
    Departments of Gastrointestinal Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, USA Electronic address
    Radiother Oncol 118:382-6. 2016
    ..This phase I study evaluated the safety and efficacy of sorafenib with infusional 5-fluorouracil (5-FU) and radiation in patients with locally advanced rectal cancer...
  12. doi Prognostic impact of lymph node retrieval and ratio in gastric cancer: a U.S. single center experience
    Joyce Wong
    Department of Gastrointestinal Oncology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL, 33612, USA
    J Gastrointest Surg 17:2059-66. 2013
    ..Increased lymph node (LN) retrieval for gastric cancer has been associated with improved overall survival (OS). This study examines the impact of number of examined LN (eLN) and lymph node ratio...
  13. ncbi The impact of body mass index on esophageal cancer
    Joyce Y Wong
    Surgical Oncology Fellowship Program, H Lee Moffitt Cancer Center, Tampa 33612, FL, USA
    Cancer Control 20:138-43. 2013
    ..Surgeons are increasingly operating on patients who are overweight or obese. The influence of obesity on surgical and oncologic outcomes has only recently been addressed. We focus this review on obesity and its impact on esophageal cancer...
  14. doi Increased survival associated with surgery and radiation therapy in metastatic gastric cancer: a Surveillance, Epidemiology, and End Results database analysis
    Ravi Shridhar
    Department of Radiation Oncology, Moffitt Cancer Center, Tampa, Florida 33612, USA
    Cancer 119:1636-42. 2013
    ..Patients with metastatic gastric cancer have poor survival. The purpose of this study was to compare outcomes of metastatic gastric cancer patients stratified by surgery and radiation therapy...
  15. ncbi Post-radiation metabolic tumor volume (MTV) and survival in esophageal cancer
    Alex Cruz
    University of South Florida College of Medicine, Tampa, FL H Lee Moffitt Cancer Center and Research Institute, Tampa, FL
    J Clin Oncol 30:9. 2012
    ..Metabolic tumor volume (MTV) has been reported as a prognostic factor in other malignancies. We evaluated the utility of post-radiation MTV in esophageal cancer patients treated with chemoradiotherapy (CRT)...
  16. doi Effect of body mass index in patients undergoing resection for gastric cancer: a single center US experience
    Joyce Wong
    Department of Gastrointestinal Oncology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL, 33612, USA
    J Gastrointest Surg 18:505-11. 2014
    ..With rising obesity in the USA, the impact of body mass index (BMI) on survival in gastric cancer remains unclear...
  17. ncbi Radiation therapy and esophageal cancer
    Ravi Shridhar
    Radiation Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Cancer Control 20:97-110. 2013
    ..Although the incidence of squamous cell carcinoma has declined, the incidence of adenocarcinoma has risen due to increases in obesity and gastroesophageal reflux disease...
  18. ncbi Effect of lymph node harvest for squamous cell cancer of the esophagus on survival
    Jeremiah Lee Deneve
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL H Lee Moffitt Cancer Center and Research Institute, Tampa, FL
    J Clin Oncol 30:102. 2012
    ..However, little is known regarding the impact of NT or nodal harvest in patients with squamous cell carcinoma (SCC) of the esophagus. We examined the extent of LN harvest and outcome in patients who underwent esophagectomy for SCC...
  19. doi The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor response
    Aaron U Blackham
    Department of Gastrointestinal Oncology, Moffitt Cancer Center and Research Institute, Tampa, Florida
    J Surg Oncol 112:597-602. 2015
    ..The prognostic significance of residual nodal disease in otherwise complete pathologic responders (ypT0N+) to neoadjuvant chemoradiation (nCRT) for esophageal cancer is unknown...
  20. doi Defining the learning curve for robotic-assisted esophagogastrectomy
    Jonathan M Hernandez
    Department of Surgery, University of South Florida, Tampa, FL, USA
    J Gastrointest Surg 17:1346-51. 2013
    ..The purpose of this study is to define the learning curve for robotic-assisted esophagogastrectomy with respect to operative time, conversion rates, and patient safety...
  21. doi Pathologic nonresponders after neoadjuvant chemoradiation for esophageal cancer demonstrate no survival benefit compared with patients treated with primary esophagectomy
    George W Dittrick
    Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA
    Ann Surg Oncol 19:1678-84. 2012
    ..This study was designed to evaluate survival in pNR to NCRT compared with patients treated with primary esophagectomy (PE)...
  22. ncbi Safety and oncologic outcomes of robotic-assisted esophagogastrectomy
    Sebastian G de la Fuente
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL H Lee Moffitt Cancer Center and Research Institute, Tampa, FL
    J Clin Oncol 30:93. 2012
    ..We report our initial experience in patients undergoing robotic-assisted Ivor-Lewis esophagogastrectomy (RAIL) for oncologic purposes at a large-referral center...
  23. ncbi Effect of lymphadenectomy on survival in patients with esophageal cancer
    Khaldoun Almhanna
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL H Lee Moffitt Cancer Center and Research Institute, Tampa, FL
    J Clin Oncol 30:65. 2012
    ..The impact of nodal harvest during esophagectomy remains to be determined. We examined the influence of lymphadenectomy on overall survival in patients with esophageal cancer...
  24. ncbi Prognostic significance of lymphadenectomy in patients with esophageal cancer receiving neoadjuvant chemoradiation
    Charmi Vijapura
    University of Missouri Kansas City School of Medicine, Kansas City, MO H Lee Moffitt Cancer Center and Research Institute, Tampa, FL
    J Clin Oncol 30:87. 2012
    ..We investigated the impact of nodal resection and survival in esophageal cancer patients treated with neoadjuvant chemoradiation (NT)...
  25. pmc Outcomes in patients with brain metastasis from esophageal carcinoma
    Nishi Kothari
    Department of Gastrointestinal Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    J Gastrointest Oncol 7:562-9. 2016
    ..To better inform management decisions, we sought to identify factors associated with survival in patients with brain metastasis from esophageal cancer...
  26. pmc Determining the optimal number of lymph nodes harvested during esophagectomy
    Khaldoun Almhanna
    Department of Gastrointestinal Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 334612, USA
    J Gastrointest Oncol 7:387-94. 2016
    ..We examined the impact of the number of lymph nodes (LNs) removed during esophagectomy on outcomes in esophageal cancer (EC)...
  27. ncbi Endoscopic therapy of neoplasia related to Barrett's esophagus and endoscopic palliation of esophageal cancer
    Shivakumar Vignesh
    Section of Endoscopic Oncology, Gastrointestinal Tumor Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Cancer Control 20:117-29. 2013
    ..Barrett's esophagus (BE) is the most important identifiable risk factor for the progression to esophageal adenocarcinoma...
  28. pmc Multimodality approach for locally advanced esophageal cancer
    Khaldoun Almhanna
    Department of Gastrointestinal Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, United States
    World J Gastroenterol 18:5679-87. 2012
    ..The role of adjuvant chemotherapy following curative resection is still unclear. External beam radiation therapy alone is considered palliative and is typically reserved for patients with a poor performance status...
  29. pmc Perioperative outcomes associated with robotic Ivor Lewis esophagectomy in patient's undergoing neoadjuvant chemoradiotherapy
    Ravi Shridhar
    1 Department of Radiation Oncology, Florida Hospital Orlando, Orlando, FL, USA 2 Department of Surgical Oncology, 3 Department of Radiation Oncology, 4 Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA 5 Department of Gastrointestinal and Surgical Oncology, Sarasota Memorial Hospital, Sarasota, FL, USA
    J Gastrointest Oncol 7:206-12. 2016
    ..The purpose of this study is to compare perioperative outcomes between patients undergoing NCR and robotic-assisted Ivor Lewis esophagectomy (RAIL) versus upfront RAIL...
  30. pmc AKT expression is associated with degree of pathologic response in adenocarcinoma of the esophagus treated with neoadjuvant therapy
    Nadia Saeed
    1 Department of Gastrointestinal Oncology, 2 Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL, USA 3 Department of Surgery, College of Medicine Florida State University, FL, USA
    J Gastrointest Oncol 7:158-65. 2016
    ..The phosphatidyl inositol 3 kinase (PI3K)/protein kinase B (AKT)/mTOR pathway plays an important role in tumorgenesis and resistance. We sought to elucidate the role of this pathway in patients with EAC who received NCRT...
  31. doi Single-institution retrospective comparison of preoperative versus definitive chemoradiotherapy for adenocarcinoma of the esophagus
    Ravi Shridhar
    Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL, USA
    Ann Surg Oncol 21:3744-50. 2014
    ..We sought to determine the impact of esophagectomy on survival in patients with adenocarcinoma of the esophagus cancer after chemoradiotherapy (CRT)...
  32. doi Stability of endoscopic ultrasound-guided fiducial marker placement for esophageal cancer target delineation and image-guided radiation therapy
    Daniel C Fernandez
    Department of Radiation Oncology, H Lee Moffitt Cancer Center, Tampa, Florida Electronic address
    Pract Radiat Oncol 3:32-9. 2013
    ..In this study, we report on the stability of endoscopic ultrasound (EUS)-guided fiducial placement for esophageal cancers and utilization for radiation treatment planning and IGRT...
  33. ncbi Low 18f-fluorodeoxyglucose uptake on positron emission tomography as a prognostic factor for stage I and II pancreatic cancer
    Jose Mario Pimiento
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL H Lee Moffitt Cancer Center and Research Institute, Tampa, FL Fox Chase Cancer Center, Philadelphia, PA
    J Clin Oncol 30:159. 2012
    ..We examined the value of PET FDG uptake in early pancreatic cancer...
  34. ncbi Her-2 Expression in Gastroesophageal Intestinal Metaplasia, Dysplasia, and Adenocarcinoma
    Khaldoun Almhanna
    Departments of Gastrointestinal Oncology Anatomic Pathology Chemical Biology and Molecular Medicine Tumor Biology, H Lee Moffitt Cancer Center, Research Institute Departments of Pathology and Cell Biology Oncological Sciences, University of South Florida, Tampa, FL
    Appl Immunohistochem Mol Morphol 24:633-638. 2016
    ..Positive Her-2 DISH in 6% of LGD is novel, suggesting a role of Her-2 during BE progression...
  35. doi Outcomes of Therasphere Radioembolization for Colorectal Metastases
    Andrea M Abbott
    Department of Surgery, Moffitt Cancer Center, Tampa, FL Electronic address
    Clin Colorectal Cancer 14:146-53. 2015
    ..Radioembolization with yttrium-90 (Y90) represents an alternative approach in the management of unresectable hepatic colorectal metastases. The objective of this study was to evaluate outcomes after treatment with Y90...
  36. doi Phase I trial of combination of FOLFIRI and pasireotide, a somatostatin analogue, in advanced gastrointestinal malignancies
    Amit Mahipal
    Department of Gastrointestinal Oncology, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive FOB 2, Tampa, FL, 33612, USA
    Invest New Drugs 33:1093-9. 2015
    ..This study aimed to evaluate the maximum tolerated dose (MTD) of pasireotide in combination with standard FOLFIRI (5-fluorouracil, leucovorin and irinotecan) regimen in patients with gastrointestinal malignancies...
  37. doi Targeted therapy for gastric adenocarcinoma
    Khaldoun Almhanna
    Department of Gastrointestinal Oncology, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Adv Pharmacol 65:437-70. 2012
    ..We have reviewed the different pathways relevant to gastric cancer development with focus on the recent advances in targeting these pathways in order to improve outcomes in this disease...
  38. pmc A phase II study of RO4929097 in metastatic colorectal cancer
    Jonathan R Strosberg
    Dept of GI Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, United States
    Eur J Cancer 48:997-1003. 2012
    ..RO4929097 is a selective inhibitor of γ-secretase. We tested the activity of RO4929097 in patients with metastatic, refractory colorectal cancer...